ArticleNature reviews bioengineering2026
The Status of Extracellular Vesicles as Drug Carriers and Therapeutics.
Article in Nature reviews bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A product control framework for extracellular vesicle therapeutics: Quality attributes, stability, analytical procedures, and biodistribution.International journal of pharmaceutics: X · 2026Review
- Hydrogel coatings for titanium implants: From smart stimuli-responsive strategies to multimodal bone regeneration.Bioactive materials · 2026Review
- Effect of extracellular vesicles on malignant tumours: Mechanisms and clinical findings (Review).Oncology letters · 2026Review
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Reprogramming the Aging Type H Vascular Niche via Myeloid Angiogenic Cell-Derived Extracellular Vesicles: Mechanisms, Engineering Strategies, and Translational Perspectives.International journal of molecular sciences · 2026Review
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- Extracellular Vesicle-Lipid Hybrid Systems for RNA Delivery in Cancer: Structural Classification, Functional Delivery, and Translational Challenges.Pharmaceutics · 2026Review
- Controlled Self-Assembly of Gold Nanoparticles for Photo-Enhanced Cancer Imaging and Treatment.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Extracellular Vesicles and Plant-Derived Vesicles in Cancer: From Mechanisms to Clinical Translation.Pharmaceutics · 2026Review
- Review
- Extracellular Vesicles as Nanoparticle Delivery Vectors in Cancer Therapy.Nano letters · 2026Review
- Emerging role of microRNAs as modulators of the tumor immune microenvironment.Journal for immunotherapy of cancer · 2026Review
- Recent advances in self-assembled nanoplatforms for central nervous system disorders therapy: Design principles, multifunctional strategies, and therapeutic applications.Materials today. Bio · 2026Review
- Recent advances in stimuli-responsive nanomaterials for the treatment of acute kidney injury.Journal of nanobiotechnology · 2026Review
- Optimizing genetic engineering approaches for protein loading into bacterial extracellular vesicles for vaginal drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- The 'sugar' side of extracellular vesicle-glycome: a panorama from basic characteristics, deciphering technologies, functions, to applications.Journal of nanobiotechnology · 2026Review
- Extracellular Vesicles in Allergy: From Cellular Communication to Clinical Implications.Clinical reviews in allergy & immunology · 2026Review
- Surface engineering of extracellular vesicles: trends, strategies, and applications in diagnosis and therapy.Journal of nanobiotechnology · 2026Review
- Extracellular Vesicles Derived from Natural Biological Resources and Their Potential to Facilitate Skin Regeneration and Rejuvenation.Pharmaceutics · 2026Review
- Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
With their natural origin and biological compatibility, extracellular vesicles (EVs) are being recognized as next-generation vehicles for targeted drug delivery. Over the last two decades, the field of EV-based drug delivery has witnessed a substantial increase in published articles. While EVs hold tremendous potential as therapeutic carriers, their utility has been limited by issues such as heterogeneity, low yields, limited cargo loading efficiency, and rapid clearance by the mononuclear phagocyte system (MPS). In this review, we examine trends across research articles published between 2012 and 2024 (n = 38,177), focusing on key developments, persistent challenges, and evolving assumptions in the field. We provide an overview of the current EV landscape, discuss their organotropism, and discuss their application as carriers for nucleic acids and other therapeutic payloads. We highlight both their strengths and weaknesses compared to lipid nanoparticles and liposomes and assess the biodistribution of EVs as a function of labeling strategy and cell sources used. Finally, we outline translational considerations for EV-based therapeutics and propose additional reporting standards, complementing the MISEV 2023 guidelines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.